WO2020150545A1 - DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE - Google Patents

DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE Download PDF

Info

Publication number
WO2020150545A1
WO2020150545A1 PCT/US2020/013983 US2020013983W WO2020150545A1 WO 2020150545 A1 WO2020150545 A1 WO 2020150545A1 US 2020013983 W US2020013983 W US 2020013983W WO 2020150545 A1 WO2020150545 A1 WO 2020150545A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
disease
optionally substituted
alkylene
unsubstituted
Prior art date
Application number
PCT/US2020/013983
Other languages
English (en)
Inventor
Sunil Kumar Kc
Chi Ching Mak
Brian Walter Eastman
Joseph Timothy Marakovits
Venkataiah Bollu
Jianguo Cao
Gopi Kumar Mittapalli
Original Assignee
Samumed, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed, Llc filed Critical Samumed, Llc
Publication of WO2020150545A1 publication Critical patent/WO2020150545A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • This disclosure relates to inhibitors of one or more proteins in the Wnt pathway, including inhibitors of one or more Wnt proteins, and compositions comprising the same. More particularly, it concerns the use of a pyrazole compound or salts or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.
  • Wnt pathway signaling e.g., cancer, abnormal
  • the Wnt growth factor family includes more than 10 genes identified in the mouse and at least 19 genes identified in the human.
  • Members of the Wnt family of signaling molecules mediate many short-and long-range patterning processes during invertebrate and vertebrate development.
  • the Wnt signaling pathway is known for its role in the inductive interactions that regulate growth and differentiation, and it also plays roles in the homeostatic maintenance of post-embryonic tissue integrity.
  • Wnt stabilizes cytoplasmic b-catenin, which stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin Dl.
  • misregulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers.
  • the Wnt pathway has also been implicated in the maintenance of stem or progenitor cells in a growing list of adult tissues including skin, blood, gut, prostate, muscle, and the nervous system.
  • Dual specificity tyrosine-phosphorylation-regulated kinase 1A is an enzyme that in humans is encoded by the DYRK1A gene.
  • DYRK1A is a member of the dual-specificity tyrosine phosphorylation -regulated kinase (DYRK) family.
  • DYRK1A contains a nuclear targeting signal sequence, a protein kinase domain, a leucine zipper motif, and a highly conservative 13- consecutive-histidine repeat. It catalyzes its autophosphorylation on serine/threonine and tyrosine residues. It may play a significant role in a signaling pathway regulating cell proliferation and may be involved in brain development.
  • DYRK1A is localized in the Down syndrome critical region of chromosome 21 , and is considered to be a candidate gene for learning defects associated with Down syndrome. DYRK1A is also expressed in adult brain neurons, indicating that DYRK1A may play a role in the mature central nervous system. Thus, several lines of evidence point to some synaptic functions of DYRK1A. For instance, it has been found that DYRK1A phosphorylates and modulates the interaction of several components of the endocytic protein complex machinery (Dynamin 1, Amphiphysin, and Synaptojanin), suggesting a role in synaptic vesicle recycling. In addition, a polymorphism (SNP) in DYRK 1 A was found to be associated with HIV-1 replication in monocyte-derived macrophages, as well as with progression to AIDS in two independent cohorts of HIV- 1 -infected individuals.
  • SNP polymorphism
  • the present disclosure provides methods and reagents, involving contacting a cell with an agent, such as a pyrazole compound, in a sufficient amount to antagonize a Wnt activity, e.g., to reverse or control an aberrant growth state or correct a genetic disorder due to mutations in Wnt signaling components.
  • an agent such as a pyrazole compound
  • the present disclosure also provides methods and reagents, involving contacting a cell with an agent, such as a pyrazole compound, in a sufficient amount to antagonize DYRK1A activity, e.g., i) to normalize prenatal and early postnatal brain development; ii) to improve cognitive function in youth and adulthood; and/or iii) to attenuate Alzheimer’s-type neurodegeneration.
  • an agent such as a pyrazole compound
  • Some embodiments disclosed herein include Wnt and/or DYRK1A inhibitors containing a pyrazole core. Other embodiments disclosed herein include pharmaceutical compositions and methods of treatment using these compounds.
  • One embodiment disclosed herein includes a compound having the structure of Formula (I):
  • R 1 is selected from the group consisting of H, halide, and unsubstituted -(C1-3 alkyl);
  • R 3 is selected from the group consisting of -heterocyclyl substituted with 1-10 R 11 , -(C1-4 alkylene) p phenyl substituted with 1-5 R 12 , -heteroaryl optionally substituted with 1-4 R 13 , and - (Ci- 4 alkylene)OR 14 ; wherein heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, 5,6,7,8-tetrahydroimidazo[l,2- a]pyrazinyl, 4,5,6,7-tetrahydro-lH-imidazo[4,5-c]pyridinyl, 1,
  • R 3 is selected from -heteroaryl optionally substituted with 1-4 R 13 ; wherein heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, 5,6,7,8-tetrahydroimidazo[l,2- a]pyrazinyl, 4,5,6,7-tetrahydro-lH-imidazo[
  • each R 4 is halide
  • each R 5 is independently selected from the group consisting of halide, Me, and Et;
  • each R 6 is independently selected from the group consisting of methyl, -CFfiF, -CHF2, - CF 3 , -OR 15a , and -(Ci-4 alkylene) p N(R 16a )(R 16b ); wherein -(C1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein;
  • R 8 is unsubstituted -(C 1-9 alkyl);
  • R 9 is unsubstituted -(C 1-9 alkyl);
  • R 10 is -aryl optionally substituted with 1-5 R 21 ;
  • each R 11 is independently selected from the group consisting of halide, methyl, and ethyl
  • R 14 is selected from the group consisting of unsubstituted -(Cw alkyl) and -aryl optionally substituted with 1-5 R 22 ; each R 15a is independently selected from the group consisting of unsubstituted -(C2-3 alkyl), and -heterocyclyl optionally substituted with 1-10 R 20b ;
  • each R 15b is independently selected from the group consisting of H, unsubstituted -(C2-9 alkyl), and -heterocyclyl optionally substituted with 1-10 R 20b ;
  • each R 16a is independently selected from the group consisting of H and unsubstituted -(Ci-
  • each R 16b is unsubstituted -(C 1-2 alkyl);
  • each R 17 is unsubstituted -(C 1-9 alkyl);
  • each R 18 is independently selected from the group consisting of H and Me;
  • each R 19 is unsubstituted -(C1-9 alkyl);
  • each R 20a is independently selected from the group consisting of halide and unsubstituted -(C 2-9 alkyl);
  • each R 20b is independently selected from the group consisting of halide and unsubstituted -(Ci-9 alkyl);
  • each R 21 is independently selected from the group consisting of halide and unsubstituted - (Ci- 9 alkyl);
  • each R 22 is independently selected from the group consisting of halide and unsubstituted - (Ci- 9 alkyl);
  • each R 23a is independently selected from the group consisting of unsubstituted -(C2-9 alkyl), — (Ci-4 alkylene)OR 25 , and -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 20b ; wherein each -(Cw alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;
  • each R 23b is independently selected from the group consisting of unsubstituted -(C1-9 alkyl), — (Ci-4 alkylene)OR 25 , and -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 20b ; wherein each -(Cw alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;
  • each R 25 is independently selected from the group consisting of H and unsubstituted -(Ci-
  • each p is independently an integer of 0 or 1.
  • Some embodiments include stereoisomers and pharmaceutically acceptable salts of a compound of Formula (I). Some embodiments include pharmaceutically acceptable salts of a compound of Formula (I).
  • Some embodiments include pro-drugs of a compound of Formula (I).
  • compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient.
  • inventions disclosed herein include methods of inhibiting one or more members of the Wnt pathway, including one or more Wnt proteins by administering to a patient affected by a disorder or disease in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, cell cycling and mutations in Wnt signaling components, a compound according to Formula (I). Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation and correct a genetic disorder due to mutations in Wnt signaling components.
  • DYRK1A includes methods of inhibiting DYRK1A by administering to a patient affected by a disorder or disease in which DYRK1A overexpression is implicated, such as Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson’s Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington’s Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor and Stroke.
  • a disorder or disease in which DYRK1A overexpression is implicated such as Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson’s Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epi
  • Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, osteochondrodysplasia, Alzheimer’s disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Miillerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/
  • Some embodiments of the present disclosure include methods to prepare compounds of Formula (I).
  • compositions and methods for inhibiting one or more members of the Wnt pathway including one or more Wnt proteins.
  • compositions and methods for inhibiting DYRK1A are provided herein.
  • Some embodiments provided herein relate to a method for treating a disease including, but not limited to, neurological diseases or disorders, cancers, chronic inflammation, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, lung disease, osteoarthritis, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis - pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Miillerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/
  • bone and cartilage diseases which can be treated with the compounds and compositions provided herein include bone spur (osteophytes), craniosynostosis, fibrodysplasia ossificans progressive, fibrous dysplasia, giant cell tumor of bone, hip labral tear, meniscal tears, osteoarthritis, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), osteochondritis dissecans, osteochondroma (bone tumor), osteopetrosis, relapsing polychondritis, and Salter-Harris fractures.
  • bone spur osteophytes
  • craniosynostosis osteophytes
  • fibrodysplasia ossificans progressive fibrous dysplasia
  • giant cell tumor of bone hip labral tear
  • meniscal tears osteoarthritis
  • articular cartilage (chondral) defects degenerative disc disease (or intervertebral disc degeneration)
  • non-limiting examples of a neurological disease or disorder associated with tau protein, amyloid or alpha-synuclein pathology which can be treated with the compounds and compositions provided herein include, but are not limited to, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson’s Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington’s Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.
  • non-limiting examples of diseases in which chronic inflammation is involved which can be treated with the compounds and compositions provided herein include eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and psoriasis), diabetes, pancreatitis, tendonitis, hepatitis, heart disease, myocarditis, stroke, lupus, and neurological disorders such as multiple sclerosis, Parkinson’s and dementia including Alzheimer’s disease.
  • non-limiting examples of cancers which can be treated with the compounds and compositions provided herein include colon, ovarian, pancreatic, breast, liver, prostate, and hematologic cancers.
  • compositions are provided that are effective for treatment of a disease of an animal, e.g., a mammal, caused by either the pathological activation or mutations of the Wnt pathway or DYRK 1 A overexpression.
  • the composition includes a pharmaceutically acceptable carrier and a compound as described herein.
  • alkyl means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, sec-pentyl and neo-pentyl.
  • Alkyl groups can either be unsubstituted or substituted with one or more substituents.
  • alkyl groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).
  • alkynyl means a straight or branched chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynyl, 1-propynyl, 1-butynyl, 2-butynyl, and the like.
  • alkynyl groups can either be unsubstituted or substituted with one or more substituents.
  • alkynyl groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
  • alkylene means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen, such as methylene, ethylene, n-propylene, iso-propylene, n-butylene, iso-butylene, sec-butylene, tert-butylene, n-pentylene, iso-pentylene, sec-pentylene and neo-pentylene.
  • Alkylene groups can either be unsubstituted or substituted with one or more substituents.
  • alkylene groups include 1 to 9 carbon atoms (for example, 1 to 6 carbon atoms, 1 to 4 carbon atoms, or 1 to 2 carbon atoms).
  • alkenylene means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon double bond, such as ethenylene, 1-propenylene, 2-propenylene, 2-methyl-l-propenylene, 1- butenylene, 2-butenylene, and the like.
  • alkenylene groups can either be unsubstituted or substituted with one or more substituents.
  • alkenylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
  • alkynylene means a bivalent branched, or straight chain chemical group containing only carbon and hydrogen and containing at least one carbon-carbon triple bond, such as ethynyl ene, 1-propynylene, 1-butynylene, 2-butynylene, and the like.
  • alkynylene groups can either be unsubstituted or substituted with one or more substituents.
  • alkynylene groups will comprise 2 to 9 carbon atoms (for example, 2 to 6 carbon atoms, 2 to 4 carbon atoms, or 2 carbon atoms).
  • alkoxy means an alkyl -O— group in which the alkyl group is as described herein.
  • exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, pentoxy, hexoxy and heptoxy, and also the linear or branched positional isomers thereof.
  • haloalkoxy means a haloalkyl-0— group in which the haloalkyl group is as described herein.
  • exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and also the linear or branched positional isomers thereof.
  • “carbocyclyl” means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl.
  • Carbocyclyls may include multiple fused rings.
  • Carbocyclyls may have any degree of saturation provided that none of the rings in the ring system are aromatic.
  • Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents. In some embodiments, carbocyclyl groups include 3 to 10 carbon atoms, for example, 3 to 6 carbon atoms.
  • aryl means a mono-, bi-, tri- or polycyclic group with only carbon atoms present in the ring backbone having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic.
  • Aryl groups can either be unsubstituted or substituted with one or more substituents. Examples of aryl include phenyl, naphthyl, tetrahydronaphthyl, 2,3-dihydro-lH- indenyl, and others. In some embodiments, the aryl is phenyl.
  • arylene means a bivalent moiety obtained by removing two hydrogen atoms of an aryl ring, as defined above.
  • arylalkylene means an aryl-alkylene- group in which the aryl and alkylene moieties are as previously described.
  • arylalkylene groups contain a Ci-4alkylene moiety.
  • exemplary arylalkylene groups include benzyl and 2-phenethyl.
  • heteroaryl means a mono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9, or 10 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S. Heteroaryl groups can either be unsubstituted or substituted with one or more substituents.
  • heteroaryl examples include thienyl, pyridinyl, ftiryl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido
  • the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, isoindolinyl, pyranyl, pyrazinyl, and pyrimidinyl.
  • heteroarylene means a bivalent moiety obtained by removing two hydrogen atoms of a heteroaryl ring, as defined above.
  • halo is a chloro, bromo, fluoro, or iodo atom radical.
  • a halo is a chloro, bromo or fluoro.
  • a halide can be fluoro.
  • haloalkyl means a hydrocarbon substituent, which is a linear or branched, alkyl, alkenyl or alkynyl substituted with one or more chloro, bromo, fluoro, and/or iodo atom(s).
  • a haloalkyl is a fluoroalkyls, wherein one or more of the hydrogen atoms have been substituted by fluoro.
  • haloalkyls are of 1 to about 3 carbons in length (e.g., 1 to about 2 carbons in length or 1 carbon in length).
  • haloalkylene means a diradical variant of haloalkyl, and such diradicals may act as spacers between radicals, other atoms, or between a ring and another functional group.
  • heterocyclyl means a nonaromatic cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 3-11 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S.
  • heterocyclyl examples include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2- dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, piperidinyl, pyrazolidinyl imidazolidinyl, thiomorpholinyl, and others.
  • the heterocyclyl is selected from azetidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and tetrahydropyridinyl.
  • “monocyclic heterocyclyl” means a single nonaromatic cyclic ring comprising at least one heteroatom in the ring system backbone. Heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, heterocycles have 3-7 members.
  • heteroatom(s) are selected from one to three of O, N or S, and wherein when the heterocycle is five membered, it can have one or two heteroatoms selected from O, N, or S.
  • heterocyclyls include azirinyl, aziridinyl, azetidinyl, oxetanyl, thietanyl, 1,4,2-dithiazolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3- dioxolanyl, morpholinyl, thiomorpholinyl, piperazinyl, pyranyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridinyl, oxazinyl, thiazinyl, thiinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, oxazolidiny
  • bicyclic heterocyclyl means a nonaromatic bicyclic ring system comprising at least one heteroatom in the ring system backbone. Bicyclic heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, bicyclic heterocycles have 4-11 members with the heteroatom(s) being selected from one to five of O, N or S. Examples of bicyclic heterocyclyls include 2 -azabicyclof 1.1.0] butane, 2- azabicyclo[2.1.0]pentane, 2-azabicyclo[l . l .
  • spirocyclic heterocyclyl means a nonaromatic bicyclic ring system comprising at least one heteroatom in the ring system backbone and with the rings connected through just one atom. Spirocyclic heterocyclyls may be substituted or unsubstituted with one or more substituents. In some embodiments, spirocyclic heterocycles have 5-11 members with the heteroatom(s) being selected from one to five of O, N or S.
  • substituted refers to moieties having substituents replacing a hydrogen on one or more non -hydrogen atoms of the molecule. It will be understood that “substitution” or“substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
  • Substituents can include, for example, -(C 1-9 alkyl) optionally substituted with one or more of hydroxyl, -NEE, -NH(C I-3 alkyl), and -N(C I -3 alkyl) 2 ; -(C1-9 haloalkyl); a halide; a hydroxyl; a carbonyl [such as -C(0)0R, and -C(0)R]; a thiocarbonyl [such as -C(S)OR, -C(0)SR, and -C(S)R]; -(C1-9 alkoxy) optionally substituted with one or more of halide, hydroxyl, -NH2, -NH(C I -3 alkyl), and -N(C I -3 alkyl)2; - OPO(OH) 2 ; a phosphonate [such as -PO(OH) 2 and -PO(OR’) 2 ]; -OPO(OR’)
  • the substituent is selected from— (Ci- 6 alkyl), -(Ci- 6 haloalkyl), a halide (e.g., F), a hydroxyl, -C(0)0R, -C(0)R, -(Ci- 6 alkoxyl), -NRR’, -C(0)NRR’, and a cyano, in which each occurrence of R and R’ is independently selected from H and -(Ci- 6 alkyl).
  • a halide e.g., F
  • the compounds provided herein may encompass various stereochemical forms.
  • the compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.
  • the present disclosure includes all pharmaceutically acceptable isotopically labeled compounds of Formula I, wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • isotopes suitable for inclusion in the compounds of the disclosure include, but are not limited to, isotopes of hydrogen, such as 2 H (deuterium) and 3 H (tritium), carbon, such as n C, 13 C and 14 C, chlorine, such as 36 C1, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 0, 17 0 and 18 0, phosphorus, such as 32 P, and sulfur, such as 35 S.
  • isotopes of hydrogen such as 2 H (deuterium) and 3 H (tritium)
  • carbon such as n C, 13 C and 14 C
  • chlorine such as 36 C1
  • fluorine such as 18 F
  • iodine such as 123 I and 125 I
  • nitrogen such as 13 N and 15 N
  • oxygen such as 15 0, 17 0 and 18 0, phosphorus, such as 32 P
  • sulfur such as 35 S.
  • administration refers to a method of providing a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally, subcutaneously, intravenously, intralymphatic, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct
  • A“diagnostic” as used herein is a compound, method, system, or device that assists in the identification or characterization of a health or disease state.
  • the diagnostic can be used in standard assays as is known in the art.
  • mammal is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, monkeys, dogs, cats, mice, rats, cows, sheep, pigs, goats, and non human primates, but also includes many other species.
  • compositions include any and all solvents, co-solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable.
  • pharmaceutically acceptable carrier includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • various adjuvants such as are commonly used in the art may be included.
  • salts refers to salts that retain the biological effectiveness and properties of the compounds provided herein and, which are not biologically or otherwise undesirable.
  • the compounds provided herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
  • “Patient” as used herein means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate, or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate.
  • the patient is a human.
  • A“therapeutically effective amount” of a compound as provided herein is one which is sufficient to achieve the desired physiological effect and may vary according to the nature and severity of the disease condition, and the potency of the compound.“Therapeutically effective amount” is also intended to include one or more of the compounds of Formula I, in combination with one or more other agents that are effective to treat the diseases and/or conditions described herein.
  • the combination of compounds can be a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Advances in Enzyme Regulation (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent.
  • a therapeutic effect relieves, to some extent, one or more of the symptoms of the disease.
  • Treatment refers to administering a compound or pharmaceutical composition as provided herein for therapeutic purposes.
  • therapeutic treatment refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, ameliorating the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder, and/or reducing the severity of symptoms that will or are expected to develop.
  • Drug-eluting and/or controlled release refers to any and all mechanisms, e.g., diffusion, migration, permeation, and/or desorption by which the drug(s) incorporated in the drug -eluting material pass therefrom over time into the surrounding body tissue .
  • Drug-eluting material and/or controlled release material as used herein refers to any natural, synthetic or semi -synthetic material capable of acquiring and retaining a desired shape or configuration and into which one or more drugs can be incorporated and from which incorporated drug(s) are capable of eluting over time.
  • “Elutable drug” as used herein refers to any drug or combination of drugs having the ability to pass over time from the drug-eluting material in which it is incorporated into the surrounding areas of the body.
  • the compounds and compositions described herein can be used as antiproliferative agents, e.g., anti-cancer and anti-angiogenesis agents, and/or as inhibitors of the Wnt signaling pathway, e.g., for treating diseases or disorders associated with aberrant Wnt signaling.
  • the compounds can be used as inhibitors of one or more kinases, kinase receptors, or kinase complexes.
  • Such compounds and compositions are also useful for controlling cellular proliferation, differentiation, and/or apoptosis.
  • the compounds and compositions described herein can be used to inhibit DYRK1A for treating a disorder or disease in which DYRK1A overexpression is implicated, such as Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson’s Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington’s Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.
  • a disorder or disease in which DYRK1A overexpression is implicated such as Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson’s Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Hunt
  • R 1 is selected from the group consisting of H, halide (e.g., F, Cl, Br, I), and unsubstituted -(C1-3 alkyl) (e.g., C1-2, Ci).
  • R 1 is selected from the group consisting of H, F, and Me.
  • R 1 is H.
  • R 2 is selected from the group consisting of unsubstituted -(C1-3 alkyl) (e.g., C1-2, Ci), unsubstituted -(C2-9 alkenyl) (e.g., C2-8, C2-7, C2-6, C2-5, C2-4, C2-3, C2), unsubstituted— (C1-9 haloalkyl) (e.g., Ci-s, C1-7, Ci- 6 , C1-5, C1-4, C1-3, C1-2, Ci),— (C1-2 alkylene) p (C3-6 carbocyclyl) optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1- 5, 1-4, 1-3, 1-2, 1) R 4 , -monocyclic heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1- 7, 1-6, 1-5, 1-4, 1-3, 1-3, 1) R 4 , -mon
  • R 2 is selected from the group consisting of unsubstituted -(C1-9 alkyl) (e.g., Ci-s, C1-7, Ci- 6 , C1-5, C1-4, C1-3, Ci- 2, Ci), unsubstituted -(C2-9 alkenyl) (e.g., C 2.8 , C2-7, C2-6, C2-5, C 2.4 , C2-3, C 2 ), unsubstituted -(C1-9 haloalkyl) (e.g., Ci-s, C1-7, Ci-
  • Ci-s, Ci-4, Ci-3, Ci- 2 Ci),— (Ci- 2 alkylene) p (C3-6 carbocyclyl) optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 4 , -monocyclic heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 5 , -phenyl substituted with 1- 5 (e.g., 1-4, 1-3, 1-2, 1) R 6 , -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 7 , - C0 2 R 8 , -OR 9 , and -(C 0)R 10 ; wherein heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, pyrazine
  • R 2 is selected from the group consisting of unsubstituted -(C1-3 alkyl) (e.g., Ci- 2, Ci), unsubstituted -(C 2 -9 alkenyl) (e.g., C 2- s, C 2- 7, C 2-6 , C 2- s, C 2-4 , C 2-3 , C 2 ), unsubstituted— (C1-9 haloalkyl) (e.g., Ci-s, C1-7, Ci- 6 , C1-5, C1-4, C1-3, Ci- 2, Ci),— (Ci- 2 alkylene) p (C3-6 carbocyclyl) optionally substituted with 1-12 (e.g., 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1- 5, 1-4, 1-3, 1-2, 1) R 4 , -monocyclic heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-
  • the heteroaryl of R 2 is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, oxadiazolyl, thiazolyl, 2,3- dihydrobenzo[b]dioxinyl, 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazinyl, 4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridinyl, isoquinolinyl, and quinolinyl.
  • R 2 is selected from the group consisting of unsubstituted -(C1-3 alkyl) (e.g., Ci- 2, Ci), -(CH 2 )(cyclopropyl), -(cyclopropyl), -monocyclic heterocyclyl optionally substituted with 1 R 5 , -phenyl substituted with 1-2 R 6 , and -pyridinyl optionally substituted with 1 R 7 .
  • -(C1-3 alkyl) e.g., Ci- 2, Ci
  • -monocyclic heterocyclyl optionally substituted with 1 R 5
  • -phenyl substituted with 1-2 R 6 e.g., -phenyl substituted with 1-2 R 6
  • -pyridinyl optionally substituted with 1 R 7 .
  • R 2 is -pyridinyl optionally substituted with 1 R 7 .
  • R 2 is selected from the group consisting of -phenyl substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R 6 and -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 7 ; wherein heteroaryl selected from the group consisting of pyridinyl, oxazolyl, oxadiazolyl, thiazolyl, 2,3- dihydrobenzo[b]dioxinyl, 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazinyl, 4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridinyl, isoquinolinyl, and quinolinyl.
  • R 3 is selected from the group consisting of -heterocyclyl substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 11 , -(Cw alkylene) p phenyl substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R 12 , -heteroaryl optionally substituted with l-4 (e.g., 1-3, 1-2, 1) R 13 , and -(Ci-4alkylene)OR 14 ; wherein heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, imidazo[4,5-b]pyridinyl
  • R 3 is selected from the group consisting of -heterocyclyl substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 11 , -(Cw alkylene) p phenyl substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R 12 , -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 13 , and -(Ci-4 alkylene)OR 14 ; wherein each -(Ci- 4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.
  • 1-10 e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1
  • R 11 e.g., -(Cw alkylene) p phenyl substituted with 1-5 (e.g., 1-4,
  • the heteroaryl of R 3 is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazinyl, 4,5,6,7-tetrahydro-lH-imidazo[4,5-c]pyridinyl,
  • R 3 is selected from the group consisting of -heterocyclyl substituted with 1 R 11 , -(Ci- 4 alkylene ) p phenyl substituted with 1 R 12 , -heteroaryl optionally substituted with 1 R 13 , and -(C2-3 alkylene)0(Ci-3 alkyl). [081] In some embodiments of Formula (I), R 3 is -pyridinyl optionally substituted with 1 R 13 .
  • R 3 is -benzimidazolyl optionally substituted with 1 R 13 .
  • R 3 is selected from -heteroaryl optionally substituted with 1-4 (e.g., 1-3, 1-2, 1) R 13 ; wherein heteroaryl selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, benzimidazolyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazinyl, 4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridinyl, 1,2,3,4-tetrahydroisoquinolinyl, isoquinoliny
  • each R 4 is halide (e.g., F, Cl, Br, I).
  • each R 5 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), Me, and Et.
  • halide e.g., F, Cl, Br, I
  • each R 6 is independently selected from the group consisting of methyl, -CFfiF, -CHF2, -CF3, -OR 15a , and -(C1-4 alkylene) p N(R 16a )(R 16b ); wherein -(C1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein.
  • the optional R 7 is independently selected from the group consisting of F, methyl, -CF3, -Oheterocyclyl optionally substituted with 1 R 20b , - (CFyheterocyclyl optionally substituted with 1-2 R 20b , -NMe2, and -(03 ⁇ 4)NMe 2 .
  • R 8 is unsubstituted -(C1-9 alkyl) (e.g., Cl-8, Cl-7, Cl-6, Cl-5, Cl-4, Cl-3, Cl-2, Cl).
  • R 9 is unsubstituted -(C1-9 alkyl) (e.g.,
  • R 10 is -aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R 21 .
  • each R 11 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I), methyl, and ethyl.
  • halide e.g., F, Cl, Br, I
  • each R 12 is independently selected from the group consisting of -(Ci- 4 alkylene) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1- 8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20a , -aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R 22 ,— (Ci-4 alkylene)N(R 16a )(R 16b ), and -OR 23a ; wherein heterocyclyl selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, and piperazinyl; wherein each -(Ci-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.
  • 1-10 e.g., 1-9, 1- 8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1
  • R 20a e.g.,
  • each R 13 is independently selected from the group consisting of F, methyl, -CFfiF, -CHF2, -CF3, -(C1-4 alkylene) p N(R 16a )2, -OR 23b , -(C1-4 alkylene) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20b , -aryl optionally substituted with 1-5 (e.g., 1-4, 1-3, 1-2, 1) R 22 , and -heteroaryl substituted with 1-4 (e.g., 1-3, 1-2, 1) R 24 ; wherein -(C1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein.
  • 1-10 e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1
  • R 20b e.g.,
  • the optional R 13 is independently selected from the group consisting of F, methyl, -CF3, -OMe, -Oheterocyclyl optionally substituted with 1 R 20b , -heterocyclyl optionally substituted with 1-2 R 20b , -(CFb)heterocyclyl optionally substituted with 1-2 R 20b , -(CFfiCFyheterocyclyl optionally substituted with 1-2 R 20b , - phenyl optionally substituted with 1 R 22 , and -heteroaryl substituted with 1 R 24 .
  • R 14 is selected from the group consisting of unsubstituted -(C1-4 alkyl) (e.g., C1-3, C1-2, Ci) and -aryl optionally substituted with 1-5 (e.g., 1- 4, 1-3, 1-2, 1) R 22 .
  • C1-4 alkyl e.g., C1-3, C1-2, Ci
  • -aryl optionally substituted with 1-5 (e.g., 1- 4, 1-3, 1-2, 1) R 22 .
  • each R 15a is independently selected from the group consisting of unsubstituted -(C2-3 alkyl) (e.g., ethyl),, and -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20b .
  • each R 15b is independently selected from the group consisting of H, unsubstituted -(C2-9 alkyl) (e.g., C2-8, C2-7, C2-6, C2-5, C2-4, C2-3, C2), and -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20b .
  • C2-9 alkyl e.g., C2-8, C2-7, C2-6, C2-5, C2-4, C2-3, C2
  • -heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 1) R 20b .
  • each R 16a is independently selected from the group consisting of H and unsubstituted -(C1-2 alkyl) (e.g. methyl).
  • each R 16b is unsubstituted -(C1-2 alkyl) (e.g. methyl).
  • each R 17 is unsubstituted -(C1-9 alkyl) (e.g., Cl-8, Cl-7, Cl-6, Cl-5, Cl-4, Cl-3, Cl-2, Cl).
  • each R 18 is independently selected from the group consisting of H and Me.
  • each R 19 is unsubstituted -(C1-9 alkyl) (e.g., Cl-8, Cl-7, Cl-6, Cl-5, Cl-4, Cl-3, Cl-2, Cl).
  • each R 20a is independently selected from the group consisting of halide (e.g., F, Cl, Br, I) and unsubstituted -(C2-9 alkyl) (e.g., C2-8, C2-7, C2-
  • halide e.g., F, Cl, Br, I
  • unsubstituted -(C2-9 alkyl) e.g., C2-8, C2-7, C2-
  • each R 20b is independently selected from the group consisting of halide (e.g., F, Cl, Br, I) and unsubstituted -(C1-9 alkyl) (e.g., Ci-s, C1-7, Ci- 6, Cl-5, Cl-4, Cl-3, Cl-2, Cl).
  • halide e.g., F, Cl, Br, I
  • unsubstituted -(C1-9 alkyl) e.g., Ci-s, C1-7, Ci- 6, Cl-5, Cl-4, Cl-3, Cl-2, Cl.
  • each R 21 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I) and unsubstituted -(C1-9 alkyl) (e.g., Ci-s, C1-7, Ci- 6, Cl-5, Cl-4, Cl-3, Cl-2, Cl).
  • halide e.g., F, Cl, Br, I
  • unsubstituted -(C1-9 alkyl) e.g., Ci-s, C1-7, Ci- 6, Cl-5, Cl-4, Cl-3, Cl-2, Cl.
  • each R 22 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I) and unsubstituted -(C1-9 alkyl) (e.g., Ci-s, C1-7, Ci-
  • each R 23a is independently selected from the group consisting of unsubstituted -(C2-9 alkyl) (e.g., C2-8, C2-7, C2-6, C2-5, C2-4, C2-3, C2), -(C1-4 alky lene) OR 25 , and -(Ci-4 alkylene) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-8, 1-
  • R 20b wherein each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.
  • each R 23b is independently selected from the group consisting of unsubstituted -(C1-9 alkyl) (e.g., Ci-s, C1-7, Ci- 6 , C1-5, C1-4, C1-3, C1-2, Ci), - (Ci-4 alkylene)OR 25 , and -(Ci-4 alkylene) p heterocyclyl optionally substituted with 1-10 (e.g., 1-9, 1-
  • each -(C1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein.
  • each R 24 is independently selected from the group consisting of halide (e.g., F, Cl, Br, I) and unsubstituted -(C1-9 alkyl) (e.g., Ci-s, C1-7, Ci- 6, Cl-5, Cl-4, Cl-3, Cl-2. Cl).
  • halide e.g., F, Cl, Br, I
  • unsubstituted -(C1-9 alkyl) e.g., Ci-s, C1-7, Ci- 6, Cl-5, Cl-4, Cl-3, Cl-2. Cl.
  • each R 25 is independently selected from the group consisting of H and unsubstituted -(C 1-9 alkyl) (e.g., Ci-s, C1-7, Ci- 6 , C1-5, Cw, C1-3, C1-2, C l ).
  • L 1 is selected from the group consisting
  • NR 18 (C 0)NR 18 -, -NH(CH 2 ) p- , and -(CH 2 ) P NH-.
  • L 1 is selected from the group consisting of a bond, -
  • L 1 is selected
  • L 1 is selected from the group
  • L 1 is selected from the group consisting of
  • L 1 is selected from the group
  • L 1 is selected from the group
  • L 1 is selected from the group
  • L 1 is selected from the
  • L 1 is selected from the group consisting of -
  • L is selected from the group consisting of a bond
  • L 1 is selected
  • L 1 is selected from the group consisting of a bond, H-; in some embodiments,
  • L 1 is selected
  • L 1 is selected from the group consisting of
  • L 1 is selected from the group consisting of -
  • L 1 is selected from the group consisting of-
  • L is selected from the group consisting of a bond, , -
  • L 1 is
  • L is selected from the group consisting of , -
  • L is selected from the group consisting of
  • L 1 is selected
  • L 1 is selected
  • L 1 is a bond; in some embodiments, L 1
  • each p is independently an integer of 0 or 1.
  • a compound of Formula I is not a compound selected from the group consisting of:
  • each -(Cw alkylene) is -(Ci-2 alkylene).
  • each -(Ci-4 alkylene) is -(Ci alkylene).
  • each -(C 1-4 alkylene) is optionally substituted with F.
  • R 1 is selected from the group consisting of H, halide, and unsubstituted -(C 1-3 alkyl);
  • R 2 is selected from the group consisting of -phenyl substituted with 1-5 R 6 and -heteroaryl optionally substituted with 1-4 R 7 ; wherein heteroaryl selected from the group consisting of pyridinyl, oxazolyl, oxadiazolyl, thiazolyl, 2,3- dihydrobenzo[b]dioxinyl, 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazinyl, 4,5,6,7-tetrahydro-lH- imidazo[4,5-c]pyridinyl, isoquinolinyl, and quinolinyl;
  • each R 5 is independently selected from the group consisting of halide, Me, and Et;
  • each R 6 is independently selected from the group consisting of -CEfF, -CHF 2 , -CF 3 , - OR 15a , and -(C 1-4 alkylene) p N(R 16a )(R 16b ); wherein -(Cw alkylene) is optionally substituted with one or more substituents as defined anywhere herein;
  • R 8 is unsubstituted -(C 1-9 alkyl);
  • R 10 is -aryl optionally substituted with 1-5 R 21 ;
  • each R 11 is independently selected from the group consisting of halide, methyl, and ethyl
  • R 14 is selected from the group consisting of unsubstituted -(C 1-4 alkyl) and -aryl optionally substituted with 1-5 R 22 ;
  • each R 15a is independently selected from -heterocyclyl optionally substituted with 1-10 j ⁇ 20b.
  • each R 15b is independently selected from the group consisting of H, unsubstituted -(C 2-9 alkyl), and -heterocyclyl optionally substituted with 1-10 R 20b ;
  • each R 16a is independently selected from the group consisting of H and unsubstituted -(Ci-
  • each R 17 is unsubstituted -(C 1-9 alkyl);
  • each R 18 is independently selected from the group consisting of H and Me;
  • each R 19 is unsubstituted -(C 1-9 alkyl);
  • each R 20a is independently selected from the group consisting of halide and unsubstituted -(C 2-9 alkyl);
  • each R 20b is independently selected from the group consisting of halide and unsubstituted -(Ci-9 alkyl); each R 21 is independently selected from the group consisting of halide and unsubstituted - (Ci- 9 alkyl);
  • each R 22 is independently selected from the group consisting of halide and unsubstituted - (Ci- 9 alkyl);
  • each R 23a is independently selected from the group consisting of unsubstituted -(C 2-9 alkyl), — (Ci- 4 alkylene)OR 25 , and -(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 20b ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;
  • each R 23b is independently selected from the group consisting of unsubstituted -(C 1-9 alkyl), — (Ci- 4 alkylene)OR 25 , and -(C 1-4 alkylene) p heterocyclyl optionally substituted with 1-10 R 20b ; wherein each -(C 1-4 alkylene) is, independently, optionally substituted with one or more substituents as defined anywhere herein;
  • each R 24 is independently selected from the group consisting of halide and unsubstituted - (Ci- 9 alkyl);
  • each R 25 is independently selected from the group consisting of H and unsubstituted -(Ci-
  • each p is independently an integer of 0 or 1.
  • each R 6 is independently selected from the group consisting of -CFfiF, -CHF2, -CF3, -OR 15a , and -(C 1-4 alkylene) p N(R 16a )(R 16b ); wherein — (Ci- 4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein.
  • each R 6 is independently selected from the group consisting of -CF3, -OR 15a , and -(C 1-4 alkylene) p N(R 16a )(R 16b ); wherein -(C 1-4 alkylene) is optionally substituted with one or more substituents as defined anywhere herein.
  • each R 15a is independently selected from -heterocyclyl optionally substituted with 1-10 R 20b .
  • compositions comprising: (a) a therapeutically effective amount of a compound provided herein, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.
  • the compounds provided herein may also be useful in combination (administered together or sequentially) with other known agents.
  • Non-limiting examples of diseases which can be treated with a combination of a compound of Formula (I) and other another active agent are colorectal cancer, ovarian cancer, chronic inflammation, diabetic retinopathy, pulmonary fibrosis, and osteoarthritis.
  • a compound of Formula (I) can be combined with one or more chemotherapeutic compounds.
  • colorectal cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: 5-Fluorouracil (5-FU), which can be administered with the vitamin-like drug leucovorin (also called folinic acid); capecitabine (XELODA ® ), irinotecan (CAMPOSTAR ® ), oxaliplatin (ELOXATIN ® ).
  • 5-FU 5-Fluorouracil
  • leucovorin also called folinic acid
  • capecitabine XELODA ®
  • CAMPOSTAR ® irinotecan
  • ELOXATIN ® oxaliplatin
  • Examples of combinations of these drugs which could be further combined with a compound of Formula (I) are FOLFOX (5- FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan) and CapeOx (Capecitabine and oxaliplatin).
  • FOLFOX 5- FU, leucovorin, and oxaliplatin
  • FOLFIRI 5-FU, leucovorin, and irinotecan
  • FOLFOXIRI leucovorin, 5-FU, oxaliplatin, and irinotecan
  • CapeOx CapeOx
  • chemo with 5-FU or capecitabine combined with radiation may be given before surgery (neoadjuvant treatment).
  • ovarian cancer can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Topotecan, Liposomal doxorubicin (DOXIL ® ), Gemcitabine (GEMZAR ® ), Cyclophosphamide (CYTOXAN ® ), Vinorelbine (NAVELBINE ® ), Ifosfamide (IFEX ® ), Etoposide (VP-16), Altretamine (HEXALEN ® ), Capecitabine (XELODA ® ), Irinotecan (CPT-11, CAMPTOSAR ® ), Melphalan, Pemetrexed (ALIMTA ® ) and Albumin bound paclitaxel (nab-paclitaxel, ABRAXANE ® ).
  • Topotecan Liposomal doxorubicin (DOXIL ® ), Gemcitabine (GEMZAR ® ), Cyclophosphamide (CYTOXAN ®
  • TIP paclitaxel [Taxol], ifosfamide, and cisplatin
  • VelP vinblastine, ifosfamide, and cisplatin
  • VIP etoposide [VP- 16], ifosfamide, and cisplatin
  • Chemotherapy using topoisomerase inhibitors such as irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, and teniposide;
  • Chemotherapy using cytotoxic antibiotics such as actinomycin, anthracyclines, doxorubicin, daunorubicin, valrubicin, idarubicin, epirubicin, bleomycin, plicamycin and mitomycin;
  • Chemotherapy using tyrosine-kinase inhibitors such as Imatinib mesylate (GLEEVEC ® , also known as STI-571), Gefitinib (Iressa, also known as ZD 1839), Erlot
  • obatoclax in clinical trials ABT-263, and Gossypol
  • PARP inhibitors e.g. Iniparib, Olaparib in clinical trials
  • PI3K inhibitors e.g. perifosine in a phase III trial
  • VEGF Receptor 2 inhibitors e.g. Apatinib
  • AN-152 e.g. AN-152, (AEZS-108)
  • Braf inhibitors e.g. vemurafenib, dabrafenib and LGX818)
  • MEK inhibitors e.g. trametinib and MEK162
  • CDK inhibitors e.g.
  • PD-0332991 PD-0332991
  • salinomycin and Sorafenib
  • Chemotherapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA ® or RITUXAN ® ), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX ® ), and Bevacizumab (marketed as AVASTIN ® ); and
  • radiation therapy e.g., radiation therapy using monoclonal antibodies such as Rituximab (marketed as MABTHERA ® or RITUXAN ® ), Trastuzumab (Herceptin also known as ErbB2), Cetuximab (marketed as ERBITUX ® ), and Bevacizumab (marketed as AVASTIN ® ); and (k) radiation therapy.
  • Rituximab marketed as MABTHERA ® or RITUXAN ®
  • diabetic retinopathy can be treated with a combination of a compound of Formula (I) and one or more of the following natural supplements: Bilberry, Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).
  • natural supplements Bilberry, Butcher's broom, Ginkgo, Grape seed extract, and Pycnogenol (Pine bark).
  • idiopathic pulmonary fibrosis/pulmonary fibrosis can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: pirfenidone (pirfenidone was approved for use in 2011 in Europe under the brand name Esbriet ® ), prednisone, azathioprine, N-acetylcysteine, interferon-g lb, bosentan (bosentan is currently being studied in patients with IPF, [The American Journal of Respiratory and Critical Care Medicine (2011), 184(1), 92-9]), Nintedanib (BIBF 1120 and Vargatef), QAX576 [British Journal of Pharmacology (2011), 163(1), 141-172], and anti-inflammatory agents such as corticosteroids.
  • pirfenidone pirfenidone was approved for use in 2011 in Europe under the brand name Esbriet ®
  • prednisone azathioprine
  • a compound of Formula (I) can be used to treat idiopathic pulmonary fibrosis/pulmonary fibrosis in combination with any of the following methods: oxygen therapy, pulmonary rehabilitation and surgery.
  • a compound of Formula (I) can be used to treat osteoarthritis in combination with any of the following methods: (a) Nonsteroidal anti inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, aspirin and acetaminophen; (b) physical therapy; (c) injections of corticosteroid medications; (d) injections of hyaluronic acid derivatives (e.g.
  • NSAIDs Nonsteroidal anti inflammatory drugs
  • Hyalgan, Synvisc Hyalgan, Synvisc
  • narcotics like codeine
  • f in combination with braces and/or shoe inserts or any device that can immobilize or support your joint to help you keep pressure off it (e.g., splints, braces, shoe inserts or other medical devices);
  • splints e.g., splints, braces, shoe inserts or other medical devices
  • realigning bones osteotomy
  • arthroplasty joint replacement
  • i) in combination with a chronic pain class a chronic pain class.
  • macular degeneration can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: Bevacizumab (Avastin ® ), Ranibizumab (Lucentis ® ), Pegaptanib (Macugen), Aflibercept (Eylea ® ), verteporfm (Visudyne ® ) in combination with photodynamic therapy (PDT) or with any of the following methods: (a) in combination with laser to destroy abnormal blood vessels (photocoagulation); and (b) in combination with increased vitamin intake of antioxidant vitamins and zinc.
  • Bevacizumab Avastin ®
  • Ranibizumab Ranibizumab
  • Pegaptanib Macugen
  • Aflibercept Eylea ®
  • verteporfm Visudyne ®
  • PDT photodynamic therapy
  • retinitis pigmentosa can be treated with a combination of a compound of Formula (I) and one or more of the following drugs: UF-021 (OcusevaTM), vitamin A palmitate and pikachurin or with any of the following methods: (a) with the Argus ® II retinal implant; and (b) with stem cell and/or gene therapy.
  • Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration, including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarilly, vaginally, rectally, ontologically, neuro- otologically, intraocularly, subconjuctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intrac
  • compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols.
  • Dosage forms such as, e.g., tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release or the like.
  • the compounds may be obtained, for example, as solid plugs, powders, or fdms by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
  • the compounds can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.
  • the compounds can be administered either alone or in combination with a conventional pharmaceutical carrier, excipient or the like.
  • Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self- emulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose -based substances,
  • Cyclodextrins such as a-, b, and g-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3- hydroxypropyl- -cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein.
  • Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared.
  • the contemplated compositions may contain 0.001%-100% of a compound provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%.
  • Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 22 nd Edition (Pharmaceutical Press, London, UK. 2012).
  • the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a compound provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like.
  • a diluent such as lactose, sucrose, dicalcium phosphate, or the like
  • a lubricant such as magnesium stearate or the like
  • a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like.
  • a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG’s, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule).
  • a capsule gelatin or cellulose base capsule.
  • Unit dosage forms in which one or more compounds provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two -compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.
  • Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. a compound provided herein and optional pharmaceutical adjuvants in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension.
  • a carrier e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like
  • the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).
  • nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (e.g., sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).
  • the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 50 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 0.25 mg/Kg to about 20 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 0.50 mg/Kg to about 19 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 0.75 mg/Kg to about 18 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 1.0 mg/Kg to about 17 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 1.25 mg/Kg to about 16 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 1.50 mg/Kg to about 15 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 1.75 mg/Kg to about 14 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 2.0 mg/Kg to about 13 mg/Kg in humans. [0292] In some embodiments, the unit dosage of compounds of Formula (I) is about 3.0 mg/Kg to about 12 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 4.0 mg/Kg to about 11 mg/Kg in humans.
  • the unit dosage of compounds of Formula (I) is about 5.0 mg/Kg to about 10 mg/Kg in humans.
  • compositions are provided in unit dosage forms suitable for single administration.
  • compositions are provided in unit dosage forms suitable for twice a day administration.
  • compositions are provided in unit dosage forms suitable for three times a day administration.
  • Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable for reconstitution in liquid prior to injection.
  • the percentage of a compound provided herein contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the patient. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.
  • the composition will comprise about 0.1-10% of the active agent in solution.
  • the composition will comprise about 0.1-5% of the active agent in solution.
  • the composition will comprise about 0.1-4% of the active agent in solution.
  • the composition will comprise about 0.15-3% of the active agent in solution.
  • the composition will comprise about 0.2-2% of the active agent in solution.
  • compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-96 hours.
  • compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-72 hours.
  • the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-48 hours.
  • compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-24 hours.
  • compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-12 hours.
  • compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of about 1-6 hours.
  • compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m 2 to about 300 mg/m 2 .
  • compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m 2 to about 200 mg/m 2 .
  • compositions can be administered by intravenous infusion to humans at doses of about 5 mg/m 2 to about 100 mg/m 2 .
  • compositions can be administered by intravenous infusion to humans at doses of about 10 mg/m 2 to about 50 mg/m 2 .
  • compositions can be administered by intravenous infusion to humans at doses of about 50 mg/m 2 to about 200 mg/m 2 .
  • compositions can be administered by intravenous infusion to humans at doses of about 75 mg/m 2 to about 175 mg/m 2 .
  • compositions can be administered by intravenous infusion to humans at doses of about 100 mg/m 2 to about 150 mg/m 2 .
  • concentrations and dosage values may also vary depending on the specific compound and the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
  • inhaled particle size For nasal delivery, a larger inhaled particle size may be desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation.
  • aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth.
  • inhaled aerodynamic particle sizes of about less than 10 pm are useful (e.g., about 1 to about 10 microns).
  • Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.
  • compounds of Formula (I) disclosed herein intended for respiratory delivery can be administered as aqueous formulations, as non-aqueous solutions or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates, or as dry powders.
  • Aqueous formulations may be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose ® or the AERx ® systems).
  • Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs).
  • Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.
  • compositions of Formula (I) disclosed herein can be administered to the ear by various methods.
  • a round window catheter e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873 can be used.
  • formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4, 164,559).
  • formulations of the disclosure can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).
  • compounds of Formula (I) disclosed herein intended for delivery to the ear can be administered via an implanted pump and delivery system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.
  • Formulations of the disclosure also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).
  • Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear.
  • the formulations described herein are administered directly onto the round window membrane via transtympanic injection.
  • the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane via a non-transtympanic approach to the inner ear.
  • the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae.
  • the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like.
  • Suppositories for rectal administration of the drug can be prepared by mixing a compound provided herein with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the compound.
  • suitable non-irritating excipient include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
  • a low-melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter, is first melted.
  • Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the compound provided herein, the desired dissolution rate, cost considerations, and other criteria.
  • the solid composition is a single unit. This implies that one unit dose of the compound is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.
  • Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, fdm-like units, foil-like units, wafers, lyophilized matrix units, and the like.
  • the solid composition is a highly porous lyophilized form.
  • Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the compound.
  • the solid composition may also be formed as a multiple unit dosage form as defined above.
  • multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like.
  • the solid composition is a lyophilized powder.
  • Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the powder is capable of absorbing water very rapidly, resulting in quick dissolution.
  • Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.
  • Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with a compound provided herein so that the compound is located at the outer surface of the individual particles.
  • the water-soluble low molecular weight excipient may be useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the compound and, for example, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film-forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.
  • kits typically include one or more compounds or compositions as described herein.
  • a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided herein, and directions for use of the kit (e.g., instructions for treating a patient).
  • the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer.
  • the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more of hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma, ovarian cancer, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, mycotic and viral infections, bone and cartilage diseases, Alzheimer’s disease, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, articular cartilage (chondral) defects, degenerative disc disease (or intervertebral disc degeneration), polyposis coli, bone density and vascular defects in the eye (Osteoporosis - pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, t
  • the compounds and compositions provided herein can be used as inhibitors and/or modulators of one or more components of the Wnt pathway, which may include one or more Wnt proteins, and thus can be used to treat a variety of disorders and diseases in which aberrant Wnt signaling is implicated, such as cancer and other diseases associated with abnormal angiogenesis, cellular proliferation, and cell cycling. Accordingly, the compounds and compositions provided herein can be used to treat cancer, to reduce or inhibit angiogenesis, to reduce or inhibit cellular proliferation, to correct a genetic disorder, and/or to treat a neurological condition/disorder/disease due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components.
  • Non-limiting examples of diseases which can be treated with the compounds and compositions provided herein include a variety of cancers, diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, scleroderma, mycotic and viral infections, bone and cartilage diseases, neurological conditions/diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (AFS), motor neuron disease, multiple sclerosis or autism, lung disease, bone/osteoporotic (wrist, spine, shoulder and hip) fractures, polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Miillerian-duct regression and virilization, SERKAF syndrome, type II diabetes, Fuhrmann syndrome, Al- Awadi/Raas-Rothschild
  • the Wnt pathway is known to be constitutively activated in a variety of cancers including, for example, colon cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, prostate cancer , pancreatic cancer and leukemias such as CML, CLL and T-ALL. Accordingly, the compounds and compositions described herein may be used to treat these cancers in which the Wnt pathway is constitutively activated.
  • the cancer is chosen from hepatocellular carcinoma, colon cancer, leukemia, lymphoma, sarcoma and ovarian cancer.
  • cancers that may be treated by the compounds, compositions and methods described herein include, but are not limited to, the following:
  • Breast cancers including, for example ER + breast cancer, ER breast cancer, her2 breast cancer, her2 + breast cancer, stromal tumors such as fibroadenomas, phyllodes tumors, and sarcomas, and epithelial tumors such as large duct papillomas; carcinomas of the breast including in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ, and invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medullary carcinoma, colloid (mucinous) carcinoma, tubular carcinoma, and invasive papillary carcinoma; and miscellaneous malignant neoplasms.
  • in situ (noninvasive) carcinoma that includes ductal carcinoma in situ (including Paget's disease) and lobular carcinoma in situ
  • invasive (infiltrating) carcinoma including, but not limited to, invasive ductal carcinoma, invasive lobular carcinoma, medu
  • breast cancers can include luminal A, luminal B, basal A, basal B, and triple negative breast cancer, which is estrogen receptor negative (ER ), progesterone receptor negative, and her2 negative (her2 ).
  • the breast cancer may have a high risk Oncotype score.
  • Cardiac cancers including, for example sarcoma, e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma; myxoma; rhabdomyoma; fibroma; lipoma and teratoma.
  • sarcoma e.g., angiosarcoma, fibrosarcoma, rhabdomyosarcoma, and liposarcoma
  • myxoma rhabdomyoma
  • fibroma fibroma
  • lipoma and teratoma.
  • Lung cancers including, for example, bronchogenic carcinoma, e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma; alveolar and bronchiolar carcinoma; bronchial adenoma; sarcoma; lymphoma; chondromatous hamartoma; and mesothelioma.
  • bronchogenic carcinoma e.g., squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma
  • alveolar and bronchiolar carcinoma bronchial adenoma
  • sarcoma sarcoma
  • lymphoma chondromatous hamartoma
  • mesothelioma mesothelioma
  • Gastrointestinal cancer including, for example, cancers of the esophagus, e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma; cancers of the stomach, e.g., carcinoma, lymphoma, and leiomyosarcoma; cancers of the pancreas, e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and vipoma; cancers of the small bowel, e.g., adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma; cancers of the large bowel, e.g., adenocarcinoma, tubular adenom
  • Genitourinary tract cancers including, for example, cancers of the kidney, e.g., adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, and leukemia; cancers of the bladder and urethra, e.g., squamous cell carcinoma, transitional cell carcinoma, and adenocarcinoma; cancers of the prostate, e.g., adenocarcinoma, and sarcoma; cancer of the testis, e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, and lipoma.
  • adenocarcinoma Wilm's tumor (nephroblastoma), lymphoma, and leukemia
  • Liver cancers including, for example, hepatoma, e.g., hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; angiosarcoma; hepatocellular adenoma; and hemangioma.
  • hepatoma e.g., hepatocellular carcinoma
  • cholangiocarcinoma e.g., hepatocellular carcinoma
  • hepatoblastoma hepatoblastoma
  • angiosarcoma hepatocellular adenoma
  • hemangioma hemangioma
  • Bone cancers including, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochrondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.
  • osteogenic sarcoma osteosarcoma
  • fibrosarcoma malignant fibrous histiocytoma
  • chondrosarcoma chondrosarcoma
  • Ewing's sarcoma malignant lymphoma (reticulum cell sarcoma)
  • multiple myeloma malignant giant cell tumor chordoma
  • Nervous system cancers including, for example, cancers of the skull, e.g., osteoma, hemangioma, granuloma, xanthoma, and osteitis deformans; cancers of the meninges, e.g., meningioma, meningiosarcoma, and gliomatosis; cancers of the brain, e.g., astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, oligodendrocytoma, schwannoma, retinoblastoma, and congenital tumors; and cancers of the spinal cord, e.g., neurofibroma, meningioma, glioma, and sarcoma.
  • the spinal cord e.g., neurofibrom
  • Gynecological cancers including, for example, cancers of the uterus, e.g., endometrial carcinoma; cancers of the cervix, e.g., cervical carcinoma, and pre tumor cervical dysplasia; cancers of the ovaries, e.g., ovarian carcinoma, including serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma, granulosa theca cell tumors, Sertoli Leydig cell tumors, dysgerminoma, and malignant teratoma; cancers of the vulva, e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, and melanoma; cancers of the vagina, e.g., clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma, and embryonal rhabdomyosarcoma;
  • Hematologic cancers including, for example, cancers of the blood, e.g., acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome, Hodgkin's lymphoma, non-Hodgkin’s lymphoma (malignant lymphoma) and Waldenstrom's macroglobulinemia.
  • Skin cancers and skin disorders including, for example, malignant melanoma and metastatic melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, and scleroderma.
  • Adrenal gland cancers including, for example, neuroblastoma.
  • tumors of the central nervous system that may be treated by the compounds, compositions and methods described herein include:
  • Astrocytic tumors e.g., diffuse astrocytoma (fibrillary, protoplasmic, gemistocytic, mixed), anaplastic (malignant) astrocytoma, glioblastoma multiforme (giant cell glioblastoma and gliosarcoma), pilocytic astrocytoma (pilomyxoid astrocytoma), pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, and gliomatosis cerebri.
  • diffuse astrocytoma fibrillary, protoplasmic, gemistocytic, mixed
  • anaplastic (malignant) astrocytoma e.g., glioblastoma multiforme (giant cell glioblastoma and gliosarcoma)
  • pilocytic astrocytoma pilomyxoid astrocytoma
  • Oligodendroglial tumors e.g., oligodendroglioma and anaplastic oligodendroglioma.
  • Oligoastrocytic tumors e.g., oligoastrocytoma and anaplastic oligoastrocytoma.
  • Ependymal tumors e.g., subependymoma, myxopapillary ependymoma, ependymoma, (cellular, papillary, clear cell, tanycytic), and anaplastic (malignant) ependymoma.
  • Choroid plexus tumors e.g., choroid plexus papilloma, atypical choroid plexus papilloma, and choroid plexus carcinoma.
  • Neuronal and mixed neuronal -glial tumors e.g., gangliocytoma, ganglioglioma, dysembryoplastic neuroepithelial tumor (DNET), dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos), desmoplastic infantile astrocytoma/ganglioglioma, central neurocytoma, anaplastic ganglioglioma, extraventricular neurocytoma, cerebellar liponeurocytoma, Papillary glioneuronal tumor, Rosette -forming glioneuronal tumor of the fourth ventricle, and paraganglioma of the fdum terminale.
  • DNET dysembryoplastic neuroepithelial tumor
  • DNET dysplastic gangliocytoma of the cerebellum
  • desmoplastic infantile astrocytoma/ganglioglioma central neurocytoma
  • anaplastic ganglioglioma extra
  • Pineal tumors e.g., pineocytoma, pineoblastoma, papillary tumors ofthe pineal region, and pineal parenchymal tumor of intermediate differentiation.
  • Embryonal tumors e.g., medulloblastoma (medulloblastoma with extensive nodularity, anaplastic medulloblastoma, desmoplastic, large cell, melanotic, medullomyoblastoma), medulloepithelioma, supratentorial primitive neuroectodermal tumors, and primitive neuroectodermal tumors (PNETs) such as neuroblastoma, ganglioneuroblastoma, ependymoblastoma, and atypical teratoid/rhabdoid tumor.
  • medulloblastoma medulloblastoma with extensive nodularity, anaplastic medulloblastoma, desmoplastic, large cell, melanotic, medullomyoblastoma
  • medulloepithelioma supratentorial primitive neuroectodermal tumors
  • PNETs neuroectodermal tumors
  • Neuroblastic tumors e.g., olfactory (esthesioneuroblastoma), olfactory neuroepithelioma, and neuroblastomas of the adrenal gland and sympathetic nervous system.
  • Glial tumors e.g., astroblastoma, chordoid glioma of the third ventricle, and angiocentric glioma.
  • Tumors of cranial and paraspinal nerves e.g., schwannoma, neurofibroma Perineurioma, and malignant peripheral nerve sheath tumor.
  • Tumors of the meninges such as tumors of meningothelial cells, e.g., meningioma (atypical meningioma and anaplastic meningioma); mesenchymal tumors, e.g., lipoma, angiolipoma, hibernoma, liposarcoma, solitary fibrous tumor, fibrosarcoma, malignant fibrous histiocytoma, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdomyosarcoma, chondroma, chondrosarcoma, osteoma, osteosarcoma, osteochondroma, haemangioma, epithelioid hemangioendothelioma, haemangiopericytoma, anaplastic haemangiopericytoma, angiosarcoma, Kaposi Sarcoma, and Ewing Sarcoma
  • Tumors of the hematopoietic system e.g., malignant Lymphomas, plasmocytoma, and granulocytic sarcoma.
  • Germ cell tumors e.g., germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, and mixed germ cell tumors.
  • Tumors of the sellar region e.g., craniopharyngioma, granular cell tumor, pituicytoma, and spindle cell oncocytoma of the adenohypophysis.
  • Cancers may be solid tumors that may or may not be metastatic. Cancers may also occur, as in leukemia, as a diffuse tissue. Thus, the term“tumor cell,” as provided herein, includes a cell afflicted by any one of the above identified disorders.
  • a method of treating cancer using a compound or composition as described herein may be combined with existing methods of treating cancers, for example by chemotherapy, irradiation, or surgery (e.g., oophorectomy).
  • a compound or composition can be administered before, during, or after another anticancer agent or treatment.
  • the compounds and compositions described herein can be used as anti- angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer and other diseases associated with cellular proliferation mediated by protein kinases.
  • the compounds described herein can inhibit the activity of one or more kinases. Accordingly, provided herein is a method of treating cancer or preventing or reducing angiogenesis through kinase inhibition.
  • the compounds and compositions described herein can function as cell-cycle control agents for treating proliferative disorders in a patient.
  • Disorders associated with excessive proliferation include, for example, cancers, scleroderma, immunological disorders involving undesired proliferation of leukocytes, and restenosis and other smooth muscle disorders.
  • such compounds may be used to prevent de -differentiation of post-mitotic tissue and/or cells.
  • Diseases or disorders associated with uncontrolled or abnormal cellular proliferation include, but are not limited to, the following:
  • cancers including, but not limited to, carcinoma, hematopoietic tumors of lymphoid lineage, hematopoietic tumors of myeloid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system and other tumors including melanoma, seminoma and Kaposi's sarcoma.
  • a disease process which features abnormal cellular proliferation e.g., benign prostatic hyperplasia, familial adenomatosis polyposis, neurofibromatosis, atherosclerosis, arthritis, glomerulonephritis, restenosis following angioplasty or vascular surgery, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.
  • Fibrotic disorders such as skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; fatty liver disease (FLD); adhesions, such as those occurring in the abdomen, pelvis, spine or tendons; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diffuse/interstitial lung disease; central nervous system fibrosis, such as fibrosis following stroke; fibrosis associated with neuro -degenerative disorders such as Alzheimer's Disease or multiple sclerosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease and radiation fibrosis
  • apoptosis-associated conditions such as cancers (including but not limited to those types mentioned herein), viral infections (including but not limited to herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV -infected individuals, autoimmune diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, sepsis, ankylosing spondylitis, psoriasis, scleroderma, autoimmune mediated glomerulonephritis, inflammatory bowel disease and autoimmune diabetes mellitus), neuro -degenerative disorders (including but not limited to Alzheimer’s disease, lung disease, amyotrophic lateral sclerosis, retinitis pigmentosa, Parkinson's disease, AIDS-related dementia, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial in
  • Wnt signaling components such as polyposis coli, bone density and vascular defects in the eye (Osteoporosis-pseudoglioma Syndrome, OPPG), familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia, Miillerian-duct regression and virilization, SERKAL syndrome, type II diabetes, Fuhrmann syndrome, Al-Awadi/Raas- Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith
  • ATRX alpha-
  • the compounds and compositions provided herein have been found to possess immunomodulatory activities and are expected to control the innate and adaptive immune system (e.g. macrophages, microglia, dendritic cells, B and T cells) and suppress pro-inflammatory cytokine release (e.g. TNF, IF-6, IF-1, IFND) which is well known to be involved in chronic inflammation in a wide variety of disease areas.
  • innate and adaptive immune system e.g. macrophages, microglia, dendritic cells, B and T cells
  • pro-inflammatory cytokine release e.g. TNF, IF-6, IF-1, IFND
  • compounds and compositions provided herein can used to treat chronic inflammation associated with disorders and diseases including but not limited to eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and psoriasis), diabetes, pancreatitis, tendonitis, hepatitis, heart disease, myocarditis, stroke, lupus, and neurological disorders such as multiple sclerosis, Parkinson’s and dementia including Alzheimer’s disease.
  • disorders and diseases including but not limited to eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic
  • the compounds and compositions provided herein can be used as inhibitors and/or modulators of the enzyme DYRK1 A, and thus can be used to treat a variety of disorders and diseases associated with tau protein, amyloid, alpha-synuclein, TDP-43 or FUS pathology including, but not limited to, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), down syndrome, frontotemporal dementia (FTD) including FTD with Parkinsonism-17 (FTDP-17), behavioural variant frontotemporal dementia (bvFTD), FTD in patients with motor neuron disease (MND) (typically amyotrophic lateral sclerosis, also called FTD-ALS), corticobasal degeneration (CBD) (also called corticobasal ganglionic degeneration), progressive supranuclear palsy, primary progressive aphasia (PPA), globular glial tauopathy (GGT), myotonic dystrophy type 1 (DM1) (also called Steinert disease), myo
  • Non-limiting examples of neurological disorders which can be treated with the compounds and compositions provided herein include Alzheimer's disease, aphasia, apraxia, arachnoiditis, ataxia telangiectasia, attention deficit hyperactivity disorder, auditory processing disorder, autism, alcoholism, Bell's palsy, bipolar disorder, brachial plexus injury, Canavan disease, carpal tunnel syndrome, causalgia, central pain syndrome, central pontine myelinolysis, centronuclear myopathy, cephalic disorder, cerebral aneurysm, cerebral arteriosclerosis, cerebral atrophy, cerebral gigantism, cerebral palsy, cerebral vasculitis, cervical spinal stenosis, Charcot-Marie-Tooth disease, Chiari malformation, chronic fatigue syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic pain, Coffm-Lowry syndrome, complex regional pain syndrome, compression neuropathy, congenital facial diplegia
  • CIDP chronic inflammatory demyelinating polyn
  • the compounds and compositions may also be useful in the inhibition of the development of invasive cancer, tumor angiogenesis and metastasis.
  • the disclosure provides a method for treating a disease or disorder associated with aberrant cellular proliferation by administering to a patient in need of such treatment an effective amount of one or more of the compounds of Formula (I), in combination (simultaneously or sequentially) with at least one other agent.
  • the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis, the method comprising administering to the patient a therapeutically effective amount of a compound according to Formula (I), or a pharmaceutically acceptable salt thereof.
  • a disorder or disease selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, bone or cartilage disease, and osteoarthritis
  • the disclosure provides a method of treating or ameliorating in a patient a disorder or disease selected from the group consisting of: chronic inflammation, systemic inflammation, diabetes, cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, a bone or cartilage disease, a neurological condition/disorder/disease, osteoarthritis, lung disease, a fibrotic disorder.
  • the pharmaceutical composition comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • the method of treats a disorder or disease in which aberrant Wnt signaling is implicated in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the disorder or disease is the pain and inflammation associated with cancer.
  • the disorder or disease is the pain and inflammation associated with a joint.
  • the disorder or disease is the pain and inflammation associated with the knee.
  • the disorder or disease is the pain and inflammation associated with the hip.
  • the disorder or disease is the pain and inflammation associated with the shoulder.
  • the disorder or disease is the pain and inflammation associated with arthritis.
  • the disorder or disease is the pain and inflammation associated with gastrointestinal disorders.
  • the disorder or disease is the pain and inflammation associated with pulmonary disorders.
  • the disorder or disease is the pain and inflammation associated with allergies.
  • the disorder or disease is the pain and inflammation associated with skin disorders.
  • the disorder or disease is the pain and inflammation associated with diabetes.
  • the disorder or disease is the pain and inflammation associated with pancreatitis.
  • the disorder or disease is the pain and inflammation associated with tendonitis. [0394] In some embodiments, the disorder or disease is the pain and inflammation associated with heart disease.
  • the disorder or disease is the pain and inflammation associated with lupus.
  • the disorder or disease is the pain and inflammation associated with a neurological disorder.
  • the disorder or disease is the pain and inflammation associated with multiple sclerosis.
  • the disorder or disease is the pain and inflammation associated with Parkinson’s.
  • the disorder or disease is cancer.
  • the disorder or disease is systemic inflammation.
  • the disorder or disease is metastatic melanoma.
  • the disorder or disease is fatty liver disease.
  • the disorder or disease is liver fibrosis.
  • the disorder or disease is tendon regeneration.
  • the disorder or disease is diabetes.
  • the disorder or disease is degenerative disc disease.
  • the disorder or disease is osteoarthritis.
  • the disorder or disease is diabetic retinopathy.
  • the disorder or disease is pulmonary fibrosis.
  • the disorder or disease is idiopathic pulmonary fibrosis
  • the disorder or disease is degenerative disc disease.
  • the disorder or disease is rheumatoid arthritis.
  • the disorder or disease is scleroderma.
  • the disorder or disease is a bone or cartilage disease.
  • the disorder or disease is a neurological disorder.
  • the disorder or disease is Alzheimer's disease.
  • the disorder or disease is osteoarthritis.
  • the disorder or disease is lung disease.
  • the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Miillerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas- Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split- hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha- thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman
  • the patient is a human.
  • the cancer is chosen from: hepatocellular carcinoma, colon cancer, breast cancer, pancreatic cancer, chronic myeloid leukemia (CMF), chronic myelomonocytic leukemia, chronic lymphocytic leukemia (CFF), acute myeloid leukemia, acute lymphocytic leukemia, Hodgkin lymphoma, lymphoma, sarcoma and ovarian cancer.
  • CMF chronic myeloid leukemia
  • CFF chronic lymphocytic leukemia
  • acute myeloid leukemia acute lymphocytic leukemia
  • Hodgkin lymphoma lymphoma
  • lymphoma lymphoma
  • sarcoma sarcoma and ovarian cancer.
  • the cancer is chosen from: lung cancer - non-small cell, lung cancer - small cell, multiple myeloma, nasopharyngeal cancer, neuroblastoma, osteosarcoma, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer - basal and squamous cell, skin cancer - melanoma, small intestine cancer, stomach (gastric) cancers, testicular cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, laryngeal or hypopharyngeal cancer, kidney cancer, Kaposi sarcoma, gestational trophoblastic disease, gastrointestinal stromal tumor, gastrointestinal carcinoid tumor, gallbladder cancer, eye cancer (melanoma and lymphoma), Ewing tumor, esophagus cancer, endo
  • the cancer is hepatocellular carcinoma.
  • the cancer is colon cancer.
  • the cancer is colorectal cancer.
  • the cancer is breast cancer.
  • the cancer is pancreatic cancer.
  • the cancer is chronic myeloid leukemia (CMF).
  • CMF chronic myeloid leukemia
  • the cancer is chronic myelomonocytic leukemia.
  • the cancer is chronic lymphocytic leukemia (CFF).
  • CFF chronic lymphocytic leukemia
  • the cancer is acute myeloid leukemia.
  • the cancer is acute lymphocytic leukemia.
  • the cancer is sarcoma.
  • the cancer is ovarian cancer.
  • the cancer is lung cancer - small cell.
  • the cancer is multiple myeloma.
  • the cancer is nasopharyngeal cancer.
  • the cancer is neuroblastoma.
  • the cancer is osteosarcoma.
  • the cancer is penile cancer.
  • the cancer is pituitary tumors.
  • the cancer is prostate cancer.
  • the cancer is retinoblastoma.
  • the cancer is rhabdomyosarcoma.
  • the cancer is salivary gland cancer.
  • the cancer is skin cancer - basal and squamous cell.
  • the cancer is skin cancer - melanoma.
  • the cancer is small intestine cancer.
  • the cancer is stomach (gastric) cancers.
  • the cancer is testicular cancer.
  • the cancer is thymus cancer.
  • the cancer is thyroid cancer.
  • the cancer is uterine sarcoma.
  • the cancer is vaginal cancer.
  • the cancer is vulvar cancer.
  • the cancer is Wilms tumor.
  • the cancer is laryngeal or hypopharyngeal cancer.
  • the cancer is kidney cancer.
  • the cancer is Kaposi sarcoma.
  • the cancer is gestational trophoblastic disease.
  • the cancer is gastrointestinal stromal tumor.
  • the cancer is gastrointestinal carcinoid tumor.
  • the cancer is eye cancer (melanoma and lymphoma). [0469] In some embodiments, the cancer is Ewing tumor.
  • the cancer is esophagus cancer.
  • the cancer is endometrial cancer.
  • the cancer is colorectal cancer.
  • the cancer is cervical cancer.
  • the cancer is brain or spinal cord tumor.
  • the cancer is bone metastasis.
  • the cancer is bone cancer.
  • the cancer is bladder cancer.
  • the cancer is bile duct cancer.
  • the cancer is anal cancer.
  • the cancer is adrenal cortical cancer.
  • the disorder or disease is a neurological condition/disorder/disease
  • the neurological condition/disorder/disease is selected from: Alzheimer's disease, frontotemporal dementias, dementia with Lewy bodies, prion diseases, Parkinson's disease, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, amyotrophic lateral sclerosis (ALS), inclusion body myositis, autism, degenerative myopathies, diabetic neuropathy, other metabolic neuropathies, endocrine neuropathies, orthostatic hypotension, multiple sclerosis and Charcot-Marie-Tooth disease.
  • ALS amyotrophic lateral sclerosis
  • the disorder or disease is a neurological condition/disorder/disease associated with tau protein, amyloid, alpha-synuclein pathology, Tar DNA-binding Protein of 43KDa (TDP-43), Prion protein PrP or fused in sarcoma (FUS).
  • tau protein amyloid, alpha-synuclein pathology, Tar DNA-binding Protein of 43KDa (TDP-43), Prion protein PrP or fused in sarcoma (FUS).
  • TDP-43 Tar DNA-binding Protein of 43KDa
  • Prion protein PrP or fused in sarcoma
  • the disorder or disease is a neurological condition/disorder/disease
  • the neurological condition/disorder/disease is selected from the group consisting of: Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Down Syndrome, Frontotemporal Dementia with Parkinsonism- 17 (FTDP-17), Lewy body dementia, Parkinson’s Disease, Pick's Disease, and additional diseases with pronounced neurodegeneration such as Autism, Dementia, Epilepsy, Huntington’s Disease, Multiple Sclerosis; diseases and disorders associated with acquired brain injury such as Chronic Traumatic Encephalopathy, Traumatic Brain Injury, Tumor, and Stroke.
  • the disorder or disease is a fibrotic disorder, wherein the fibrotic disorder is selected from the group consisting of: skin fibrosis; scleroderma; progressive systemic fibrosis; lung fibrosis; muscle fibrosis; kidney fibrosis; glomerulosclerosis; glomerulonephritis; hypertrophic scar formation; uterine fibrosis; renal fibrosis; cirrhosis of the liver, liver fibrosis; adhesions; chronic obstructive pulmonary disease; fibrosis following myocardial infarction; pulmonary fibrosis; fibrosis and scarring associated with diff ise/interstitial lung disease; central nervous system fibrosis; fibrosis associated with proliferative vitreoretinopathy (PVR); restenosis; endometriosis; ischemic disease, and radiation fibrosis.
  • the fibrotic disorder is selected from the group consisting of: skin fibrosis; scleroderma; progressive system
  • the disorder or disease is chronic inflammation associated with eye disorders, joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and psoriasis), diabetes, pancreatitis, tendonitis, hepatitis, heart disease, myocarditis, stroke, lupus, and neurological disorders such as multiple sclerosis, Parkinson’s and dementia including Alzheimer’s disease.
  • eye disorders joint pain, arthritis (rheumatoid, osteo, psoriatic gout), cancers (colon, breast, lung, pancreas, and others), gastrointestinal disorders (ulcerative colitis and inflammatory bowel diseases), pulmonary disorders (chronic obstructive pulmonary disorder and asthma), allergies, skin disorders (atopic dermatitis and
  • a compound of Formula (I) inhibits DYRK1A.
  • a compound of Formula (I) inhibits GSK3.
  • a compound of Formula (I) inhibits GSK3 .
  • a compound of Formula (I) inhibits DYRK1A and
  • the compound of Formula (I) inhibits one or more proteins in the Wnt pathway.
  • the compound of Formula (I) inhibits signaling induced by one or more Wnt proteins.
  • the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.
  • the compound of Formula (I) inhibits a kinase activity.
  • the method treats a disease or disorder mediated by the
  • the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the compound of Formula (I) inhibits one or more Wnt proteins.
  • the method treats a disease or disorder mediated by kinase activity in a patient, the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the disease or disorder comprises tumor growth, cell proliferation, or angiogenesis.
  • the method inhibits the activity of a protein kinase receptor, the method comprises contacting the receptor with an effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the method treats a disease or disorder associated with aberrant cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the method prevents or reduces angiogenesis in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the method prevents or reduces abnormal cellular proliferation in a patient; the method comprises administering to the patient a therapeutically effective amount of a compound (or compounds) of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the method treats a disease or disorder associated with aberrant cellular proliferation in a patient, the method comprises administering to the patient a pharmaceutical composition comprising one or more of the compounds of claim 1 in combination with a pharmaceutically acceptable carrier and one or more other agents.
  • Compounds and compositions described herein can inhibit the kinase activity of, for example, CDK/cyclin complexes, such as those active in the Go or Gi stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.
  • CDK/cyclin complexes such as those active in the Go or Gi stage of the cell cycle, e.g., CDK2, CDK4, and/or CDK6 complexes.
  • the biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art, see, e.g., WO 2001/053268 and WO 2005/009997.
  • the activity of a compound may be tested using one or more of the test methods outlined below.
  • tumor cells may be screened for Wnt independent growth.
  • tumor cells of interest are contacted with a compound (i.e. inhibitor) of interest, and the proliferation of the cells, e.g. by uptake of tritiated thymidine, is monitored.
  • tumor cells may be isolated from a candidate patient who has been screened for the presence of a cancer that is associated with a mutation in the Wnt signaling pathway.
  • Candidate cancers include, without limitation, those listed above.
  • one may utilize in vitro assays for Wnt biological activity e.g. stabilization of b-catenin and promoting growth of stem cells.
  • Assays for biological activity of Wnt include stabilization of b-catenin, which can be measured, for example, by serial dilutions of a candidate inhibitor composition.
  • An exemplary assay for Wnt biological activity contacts a candidate inhibitor with cells containing constitutively active Wnt ⁇ -catenin signaling. The cells are cultured for a period of time sufficient to stabilize b-catenin, usually at least about 1 hour, and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with antibodies specific for b-catenin.
  • the activity of a candidate compound can be measured in a Xenopus secondary axis bioassay (Leyns, L. et al. Cell (1997), 88(6), 747-756).
  • in vitro assays for DYRK1A biological activity may be used, e.g. regulation of microtubule-associated protein tau (MAPT/Tau) phosphorylation in neuronal cell line such as the human SH-SY5Y neuroblastoma cell line.
  • Assays for DYRK1A- regulated level of phosphorylation can include monitoring levels of basal pSer396 Tau, which can be measured, for example, by serial dilutions of a candidate inhibitor composition using a ten micromolar top concentration and detected by ELISA or Western Blotting.
  • An exemplary assay for DYRK-1 A-regulated phosphorylation uses the SH-SY 5Y cells cultured in a 96 well plate format for a period of time sufficient to stabilize microtubules and Tau phosphorylation, usually at least 2 days, then treated with a 1/3 serial dilution of compounds overnight and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with an antibody specific for pSer396 Tau. The chemiluminescence signal for HRP -linked antibodies used in western blotting is detected using a Carestream Image Station and blot densitometry for pSer396 and beta-actin are analyzed using Image J (NIH).
  • the activity of a candidate compound can be measured by ELISA by adding the lysate mentioned above onto total Tau-coated plates and detected with a specific pSer396 antibody. Colorimetric detection of ELISA signal is performed by Cytation3 plate reader (Biotek).
  • the peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; ddd, doublet of doublets of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; dq, doublet of quartets; m, multiplet.
  • Boc / -butyloxycarbonyl group
  • DIAD diisopropyl azodicarboxylate
  • DIPEA N,N-diisopropylethylamine
  • HATU l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
  • LAH lithium aluminum hydride
  • LC/MS Liquid chromatography-mass spectrometry
  • Ms mesyl or methanesulfonyl group
  • NaBH(OAc) 3 sodium triacetoxyborohydride
  • NaCNB3 ⁇ 4 sodium cyanoborohydride
  • NaHS03 sodium bisulfite
  • NIS N-iodosuccinimide
  • Pd(dba) 3 tris(dibenzylideneacetone)dipalladium(0)
  • Pd(dppf)Cl2 1.1 '-bis(diphcnylphosphino)fcrroccnc-palladium(//)dichloridc
  • Pd(PPli 3 ) 2 Cl 2 bis(triphenylphosphine)palladium(II) dichloride
  • Pd(PPli3)4 tetrakis(triphenylphosphine)palladium(0)
  • Pd(t-Bu3P)2 Bis(tri-/er/-butylphosphine)palladium(0)
  • PE petroleum ether
  • pTsOH p-toluenesulfonic acid or tosylic acid
  • xanthphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
  • Scheme 1 describes a method for preparation of pyrazole intermediate (V) by first iodination using NIS in the presence of TFA to give pyrazole (II) followed by protection of the pyrazole nitrogen by THP.
  • the methyl ester of pyrazole (III) was then hydrolyzed to acid (IV) followed by coupling with N,O-dimethylhydroxylamine to form the Weinreb amide (V).
  • Scheme 2 describes a method for preparation of pyrazole intermediate (XIX) by first iodination using NIS in the presence of TFA to give pyrazole (VII) followed by protection of the pyrazole nitrogen by THP.
  • the protected iodo pyrazole (VIII) was coupled to TMS protected acetylene in the presence of catalytic palladium and copper to give alkyne substituted pyrazole (IX).
  • the TMS protecting group was removed using Li OH followed by Sonogashira coupling of the terminal alkyne with various R 2 -bromines to produce pyrazole (XIX).
  • Scheme 4 describes methods for the preparation of pyrazole intermediates (XXI), (XXIV), and (XXVII) from pyrazole intermediate (VIII).
  • XXI alkyne substituted pyrazol-3-yl-benzoimidazole
  • Sonogashira cross-coupling reaction was used to couple intermediate (VIII) with various substituted alkynes to form (XIX) followed by cyclization with various phenylenediamines to give the benzimidazole (XX) followed by deprotection to yield the final pyrazol-3-yl-benzoimidazole (XXI) derivatives.
  • alkene substituted pyrazol-3-yl- benzoimidazole (XXIV) various substituted alkenes were coupled to pyrazole intermediate (VIII) using the Heck reaction to form (XXII) followed cyclization with various phenylenediamines to give the benzimidazole (XXIII) followed by deprotection to yield the final pyrazol-3-yl- benzoimidazole (XXIV) derivatives.
  • Scheme 5 describes methods for the preparation of pyrazole intermediates (XXXVI) and (XL) from pyrazole intermediate (XXXII).
  • XXXVI diamide pyrazole
  • XXXVII diamide pyrazole
  • XXXIII The amine pyrazole (XXXII) was coupled with various acids to give XXXIII followed by hydrolysis of the ester to give the acid (XXXIV).
  • Acid (XXXIV) was coupled with various amines followed by deprotection to yield the final diamide pyrazole (XXXVI) derivatives.
  • CXXXIII The solution containing l-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- indazole (CXXXIII) was cooled to room temperature before adding 3,5-dibromo-4-nitro-l- (tetrahydro-2H-pyran-2-yl)-lH-pyrazole (CXXXI) (1.0 g, 2.82 mmol, 1 eq), Pd(PPh3)4 (160 mg, 0.14 mmol, 0.05 eq), K3PO4 (1.2 g, 5.6 mmol, 2 eq), and water (2 mL).

Abstract

L'invention concerne des composés de pyrazole (I) pour le traitement de diverses maladies et pathologies. Plus particulièrement, la présente invention concerne l'utilisation de composés de pyrazole, dans le traitement de troubles caractérisés par l'activation de la signalisation de la voie Wnt (par exemple le cancer, la prolifération cellulaire anormale, l'angiogenèse, la maladie d'Alzheimer, les maladies pulmonaires, l'inflammation, les maladies auto-immunes et l'arthrose), la modulation d'événements cellulaires médiés par la signalisation de la voie Wnt, ainsi que des états/troubles/maladies neurologiques liés à la surexpression de DYRK1A.
PCT/US2020/013983 2019-01-17 2020-01-17 DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE WO2020150545A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962793428P 2019-01-17 2019-01-17
US62/793,428 2019-01-17
US201962831478P 2019-04-09 2019-04-09
US62/831,478 2019-04-09

Publications (1)

Publication Number Publication Date
WO2020150545A1 true WO2020150545A1 (fr) 2020-07-23

Family

ID=69529083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/013983 WO2020150545A1 (fr) 2019-01-17 2020-01-17 DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE

Country Status (1)

Country Link
WO (1) WO2020150545A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114276338A (zh) * 2022-01-06 2022-04-05 苏州大学 2-吡唑-3-苯并咪唑衍生物及其制备方法和应用
EP3813826A4 (fr) * 2018-06-26 2022-07-06 BioSplice Therapeutics, Inc. Méthodes de traitement du cancer à l'aide d'un inhibiteur de clk
US11548872B2 (en) 2016-04-27 2023-01-10 Biosplice Therapeutics, Inc. Isoquinolin-3-yl carboxamides and preparation and use thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
WO1987005297A1 (fr) 1986-03-03 1987-09-11 The University Of Chicago Derives de cephalosporines
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
WO2001053268A2 (fr) 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire
US6377849B1 (en) 1998-11-19 2002-04-23 Thomas Lenarz Catheter for applying medication into the endolymphatic sacs of the cochlea
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
WO2005009997A1 (fr) 2003-07-30 2005-02-03 Pfizer Inc. Composes d'indazole 3,5 disubstitutes, compositions pharmaceutiques, et procedes pour medier ou inhiber la proliferation cellulaire
WO2005012256A1 (fr) * 2003-07-22 2005-02-10 Astex Therapeutics Limited Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3)
US6911211B2 (en) 2000-01-10 2005-06-28 Foamix Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
WO2008007123A2 (fr) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Composés pharmaceutiques
WO2015143380A1 (fr) * 2014-03-20 2015-09-24 Samumed, Llc Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
WO2017024015A1 (fr) * 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
WO1987005297A1 (fr) 1986-03-03 1987-09-11 The University Of Chicago Derives de cephalosporines
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
US6377849B1 (en) 1998-11-19 2002-04-23 Thomas Lenarz Catheter for applying medication into the endolymphatic sacs of the cochlea
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6911211B2 (en) 2000-01-10 2005-06-28 Foamix Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
WO2001053268A2 (fr) 2000-01-18 2001-07-26 Agouron Pharmaceuticals, Inc. Composes d'indazole, compositions pharmaceutiques, et methodes destines a la mediation ou a l'inhibition de la proliferation cellulaire
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
WO2005012256A1 (fr) * 2003-07-22 2005-02-10 Astex Therapeutics Limited Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3)
WO2005009997A1 (fr) 2003-07-30 2005-02-03 Pfizer Inc. Composes d'indazole 3,5 disubstitutes, compositions pharmaceutiques, et procedes pour medier ou inhiber la proliferation cellulaire
WO2008007123A2 (fr) * 2006-07-14 2008-01-17 Astex Therapeutics Limited Composés pharmaceutiques
WO2015143380A1 (fr) * 2014-03-20 2015-09-24 Samumed, Llc Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
WO2017024015A1 (fr) * 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Comprehensive Organic Transformations: A Guide to Functional Group Transformations", 1999, JOHN WILEY & SONS
"Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 13th Ed.", 2017, THE MCGRAW-HILL COMPANIES
"March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure 7th Ed.", 2013, JOHN WILEY & SONS
"Remington: The Science and Practice of Pharmacy", 2012, PHARMACEUTICAL PRESS
BRITISH JOURNAL OF PHARMACOLOGY, vol. 163, no. 1, 2011, pages 141 - 172
CAREYSUNDBERG: "Advanced Organic Chemistry 5th Ed.", 2007, SPRINGER
CHOUTALALAY, ADVANCES IN ENZYME REGULATION, vol. 22, 1984, pages 27 - 55
LEYNS, L. ET AL., CELL, vol. 88, no. 6, 1997, pages 747 - 756
P. WUTS: "Greene's Protective Groups in Organic Synthesis", 2014, JOHN WILEY & SONS
SURAM DURGAMMA ET AL: "Synthesis and antioxidant activity of amido-linked benzoxazolyl/benzothiazolyl/benzimidazolyl-pyrroles and pyrazoles", MEDICINAL CHEMISTRY RESEARCH., vol. 23, no. 6, 1 June 2014 (2014-06-01), US, pages 2916 - 2929, XP055682333, ISSN: 1054-2523, DOI: 10.1007/s00044-013-0884-x *
THE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 184, no. 1, 2011, pages 92 - 9
WATTS, K. L.: "RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis", RESPIRATORY RESEARCH, vol. 7, no. 1, 2006, pages 88, XP021013367, DOI: 10.1186/1465-9921-7-88
XIAOQIU LIU: "Fibrotic Lung Fibroblasts Show Blunted Inhibition by cAMP Due to Deficient cAMP Response Element-Binding Protein Phosphorylation", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 315, no. 2, 2005, pages 678 - 687

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11548872B2 (en) 2016-04-27 2023-01-10 Biosplice Therapeutics, Inc. Isoquinolin-3-yl carboxamides and preparation and use thereof
EP3813826A4 (fr) * 2018-06-26 2022-07-06 BioSplice Therapeutics, Inc. Méthodes de traitement du cancer à l'aide d'un inhibiteur de clk
CN114276338A (zh) * 2022-01-06 2022-04-05 苏州大学 2-吡唑-3-苯并咪唑衍生物及其制备方法和应用
WO2023130541A1 (fr) * 2022-01-06 2023-07-13 苏州大学 Dérivé de 2-pyrazole-3-benzimidazole, son procédé de préparation et son utilisation
CN114276338B (zh) * 2022-01-06 2023-11-28 苏州大学 2-吡唑-3-苯并咪唑衍生物及其制备方法和应用

Similar Documents

Publication Publication Date Title
US10947217B2 (en) Isoquinolin-3-YL carboxamides and preparation and use thereof
US10280166B2 (en) 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof
US10669240B2 (en) 5-substituted indazole-3-carboxamides and preparation and use thereof
AU2017258187B2 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
US10350199B2 (en) 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US9475807B2 (en) 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof
WO2017024015A1 (fr) 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017023988A1 (fr) 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
WO2017023989A1 (fr) 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines et leurs utilisations thérapeutiques
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
WO2019079626A1 (fr) 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
WO2019084497A1 (fr) 6-(hétéroaryle et aryle à 6 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
WO2019084496A1 (fr) 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl-(hétéroaryle à 5 chaînons)carboxamides, leur préparation et leur utilisation
WO2020150545A1 (fr) DÉRIVÉS DE PYRAZOLE UTILISÉS COMME MODULATEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
WO2019241540A1 (fr) Macrocycles contenant de l'indazole et utilisations thérapeutiques associées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20704763

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20704763

Country of ref document: EP

Kind code of ref document: A1